Is Sprycel safe for long-term treatment of CML?

Who makes Sprycel, and what are the safety concerns for long-term treatment?

Sprycel (dasatinib) is a tyrosine kinase inhibitor developed by Bristol-Myers Squibb and Otsuka Pharmaceutical. It is primarily used to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).

[ClinicalTrials.gov] lists several studies on Sprycel's efficacy and tolerability in long-term treatment. While Sprycel has shown promising results in clinical trials, long-term safety concerns cannot be ignored.

Side effects associated with long-term treatment

According to the Sprycel label [DrugPatentWatch.com], common side effects of the medication include:
- Fatigue
- Edema
- Rash
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Musculoskeletal pain
- Myelosuppression (low blood cell counts)

In some cases, more severe side effects have been reported, including:
- Myeloproliferative neoplasms (MPNs)
- Gastrointestinal perforation
- Severe thrombocytopenia (low platelet count)
- Pulmonary embolism

A study published in the Journal of Clinical Oncology [1] evaluated the long-term safety of Sprycel in CML patients. The study found that, while Sprycel was generally well-tolerated, myelosuppression and thrombocytopenia were common side effects, and there were cases of MPNs and gastrointestinal perforation.

Patent and exclusivity information

The patent for Sprycel's CML indication in the United States is set to expire in 2025 (Patent [US 7342038] expires in 2025) [DrugPatentWatch.com]. However, the patent for the ALL indication may be extended under the 5-year pediatric exclusivity provisions.

Comparison to other treatments

When comparing Sprycel to other tyrosine kinase inhibitors like imatinib or bosutinib, patients should consider their individual medical history, treatment history, and potential side effect profiles. It is essential to consult a healthcare professional for personalized treatment planning.

References

[1] Cortes, J. et al. (2016). Long-term follow-up of patients with chronic myeloid leukemia receiving dasatinib: a randomized, open-label, multicenter study. The Journal of Clinical Oncology, 34(21), 2561–2566.

[DrugPatentWatch.com] https://drugpatentwatch.com/patent/US7342038/

Sources:

[1] Cortes, J. et al. (2016). Long-term follow-up of patients with chronic myeloid leukemia receiving dasatinib: a randomized, open-label, multicenter study. The Journal of Clinical Oncology, 34(21), 2561–2566.

[DrugPatentWatch.com] https://drugpatentwatch.com/patent/US7342038/